Home » Stocks » BBIO

BridgeBio Pharma, Inc. (BBIO)

Stock Price: $50.72 USD 1.24 (2.51%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $50.85 +0.13 (0.25%) May 13, 4:11 PM
Market Cap 7.33B
Revenue (ttm) 8.71M
Net Income (ttm) -519.95M
Shares Out 138.63M
EPS (ttm) -4.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $50.72
Previous Close $49.48
Change ($) 1.24
Change (%) 2.51%
Day's Open 49.67
Day's Range 49.56 - 51.86
Day's Volume 923,024
52-Week Range 26.17 - 73.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -35.63% and -95.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

–Received U.S. Food and Drug Administration (FDA) approval for NULIBRY™ (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency...

1 week ago - GlobeNewsWire

Viking Global leader Andreas Holversen disclosed a stake in Mudrick Capital Acquistion Corp. II (NASDAQ:MUDS) earlier this month, seeing yet another value opportunity in special purpose acquisition comp...

Other stocks mentioned: ADPT, DIS, FIS, MSFT, MUDS, TMUS
3 weeks ago - GuruFocus

PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate researc...

1 month ago - GlobeNewsWire

PALO ALTO, Calif. and SACRAMENTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis), to...

1 month ago - GlobeNewsWire

PALO ALTO, Calif. and BUFFALO, N.Y., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Roswell Park Comprehensive Cancer Center to advance the...

1 month ago - GlobeNewsWire

PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Oregon Health & Science University (OHSU) in Portland, Oregon, to advance...

1 month ago - GlobeNewsWire

TORRANCE, Calif. and PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center t...

1 month ago - GlobeNewsWire

PALO ALTO, Calif. and EDMONTON, Alberta, April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) and the Canadian Glycomics Network (GlycoNet), a pan-Canadian Network of Centres of Exce...

1 month ago - GlobeNewsWire

PALO ALTO, Calif. and PROVIDENCE, R.I., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), and Brown University today announced a formal collaboration to advance research in genet...

1 month ago - GlobeNewsWire

PALO ALTO, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on April 5, 2021...

1 month ago - GlobeNewsWire

At the start of March, BridgeBio Pharma Inc (NASDAQ: BBIO) won approval for its first drug, fosdenopterin, for sporadic cases of molybdenum cofactor deficiency type A. In the middle of March, it announc...

1 month ago - Benzinga

- BridgeBio, through its affiliate QED (“BridgeBio”), and Helsinn to co-commercialize infigratinib for oncology and all other indications other than skeletal dysplasia indications in the U.S. and equall...

1 month ago - GlobeNewsWire

It's worth putting a few of your eggs into this basket if you're worried about a big increase in prices.

Other stocks mentioned: HALO
1 month ago - The Motley Fool

– Normalization of Blood Calcium and Urine Calcium in 6 of 6 (100%) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Participants Initially Evaluated Over 5 Days Demonstrates Proof-of-Concept

1 month ago - GlobeNewsWire

Viking Global leader Andreas Holversen disclosed a stake in Orion Acquisition Corp. (NASDAQ:OHPAU) earlier this month, joining a growing number of investors who are seeing value opportunities in special...

Other stocks mentioned: ADPT, FIS, MSFT, TMUS
1 month ago - GuruFocus

Looking through the 13F reports filed by hedge funds over the past few weeks, it's clear that these investors are betting on technology.

Other stocks mentioned: FB, MSFT, TMUS, VZ
2 months ago - GuruFocus

PALO ALTO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 1, 2021...

2 months ago - GlobeNewsWire

BridgeBio Pharma Inc (NASDAQ: BBIO) and affiliate Origin Biosciences Inc have received the FDA approval for Nulibry (fosdenopterin) Injection to reduce the risk of mortality in patients with molybdenum ...

2 months ago - Benzinga

Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high inf...

2 months ago - GlobeNewsWire

BridgeBio Pharma (BBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -17.44% and -99.21%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

–Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory appr...

2 months ago - GlobeNewsWire

Company to Host Webcast to Discuss Proof-of-Concept Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 on March 22 at 8:00 a.m. ET Company to Host Webcast to Discuss Proof-of-Concept Data for ...

2 months ago - GlobeNewsWire

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

With the trading day more than halfway over, the broad markets could not make up their mind on a direction.

Other stocks mentioned: FL, NVDA, PBR, PBR.A, DAL, ALNY, FREE ...
2 months ago - 24/7 Wall Street

BridgeBio Pharma Inc (NASDAQ: BBIO) and affiliate ML Bio Solutions have dosed the first patient in the Phase 2 trial evaluating BBP-418 in patients with Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i). ...

2 months ago - Benzinga

SAN FRANCISCO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for ...

2 months ago - GlobeNewsWire

PALO ALTO, Calif. , Feb. 12, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of a secondary public offering of 3,000,000 s...

3 months ago - GlobeNewsWire

PALO ALTO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the launch of a secondary public offering of 3,000,000 sha...

3 months ago - GlobeNewsWire

PALO ALTO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 1, 20...

3 months ago - GlobeNewsWire

PALO ALTO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Venthera, which is focused on developing new treatment options for patients with rare vascular an...

3 months ago - GlobeNewsWire

BridgeBio recently merged with Eidos, of which it previously owned 64%. AG10 is Eidos' lead asset.

3 months ago - Seeking Alpha

PALO ALTO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate principal amount of ...

3 months ago - GlobeNewsWire

PALO ALTO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and...

3 months ago - GlobeNewsWire

PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced that the ...

3 months ago - GlobeNewsWire

PALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today that the ...

4 months ago - GlobeNewsWire

Here's why the biggest biotech IPO of 2019 outshines all its peers.

4 months ago - The Motley Fool

PALO ALTO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on January 4, 202...

4 months ago - GlobeNewsWire

Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.

Other stocks mentioned: EDIT, FATE
4 months ago - The Motley Fool

PALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommends that Bri...

4 months ago - GlobeNewsWire

SAN FRANCISCO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genet...

4 months ago - GlobeNewsWire

According to current portfolio statistics, a Premium feature of GuruFocus, the top five health care positions in Andreas Halvorsen (Trades, Portfolio)'s equity portfolio as of the third quarter are Adap...

Other stocks mentioned: ADPT, BSX, CNC, TMO
4 months ago - GuruFocus

Contour Therapeutics Brings Together Leaders with Extensive Cardiovascular, Genetics and Drug Development Expertise

5 months ago - GlobeNewsWire

PALO ALTO, Calif., Dec. 04, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on December 1, 20...

5 months ago - GlobeNewsWire

This company's about to begin delivering a stream of new drugs that target genetic diseases, and hardly anyone's heard about it.

5 months ago - The Motley Fool

WILMINGTON, Del., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating BridgeBio Pharma, Inc. (“BridgeBio”) (NASDAQ GS: BBIO) regarding possible breaches of fiduci...

5 months ago - GlobeNewsWire

•  Application accepted under P riority R eview designation •  Application accepted into Real Time Oncology Review (RTOR) pilot program •  This is BridgeBio's s econd NDA a cceptance •  Application will...

5 months ago - GlobeNewsWire

SAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Navire Pharma, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial...

6 months ago - GlobeNewsWire

China Grand Pharma announced a $340 million agreement to develop and commercialize Telix Pharma's molecularly-targeted radiation products in China. JW Therapeutics, a Shanghai cell therapy company, rais...

6 months ago - Seeking Alpha

About BBIO

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoin... [Read more...]

Industry
Biotechnology
IPO Date
Jun 27, 2019
CEO
Neil Kumar
Employees
385
Stock Exchange
NASDAQ
Ticker Symbol
BBIO
Full Company Profile

Financial Performance

In 2020, BBIO's revenue was $8.25 million, a decrease of -79.66% compared to the previous year's $40.56 million. Losses were -$448.72 million, 72.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is 83.13, which is an increase of 63.90% from the latest price.

Price Target
$83.13
(63.90% upside)
Analyst Consensus: Buy